Hi @markeewan I continued the use of 20% of revenue simply because that was the example used by Mozzarc in the post I cross referenced my post to. But in addition to that, it makes sense to me that PAR will have to partner with a Big Pharma company to ramp up marketing and distribution and it’s a physical product so there will be costs involved in shipping, storage, insurance etc, etc... so no one involved in the process gets 100% of top line revenue.
Year 1 Revenue, page-18
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.5¢ |
Change
-0.005(2.27%) |
Mkt cap ! $75.23M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 22.0¢ | 21.0¢ | $129.2K | 602.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 136433 | 21.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.0¢ | 54545 | 2 |
View Market Depth
| Last trade - 16.10pm 07/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |